Designated as a developing resource in January 2005, the Pharmacokinetics/ Pharmacodynamics (PK/PD) Resource is a new CCSG Resource. Its mission is to support clinical and preclinical drug development at RPCI by providing quality analytical data using sensitive methods for PK/PD studies of cancer therapeutic and preventive agents with quality assurance, cost effectiveness and necessary modeling support. It also provides small molecule quantification for investigators. The Resource is organized into two sections: the Clinical/Preclinical Drug Development directed by Lakshmi Pendyala, PhD, and the Steroid Hormone and Vitamin D Section directed by Josephia Muindi, MD, PhD. Technical personnel consist of a Mass Spectrometrist, 1.5 FTE research associates and two technicians. The Resource provides: 1) consultation and input for PK/PD studies for protocol, CTEP/LOI and grant preparations;2) development and validation of analytical assays for new small molecules;3) extraction of drugs/ metabolites from biological matrices and analysis by using LC/MS/MS, UPLC, HPLC, Atomic Absorption;4) real-time qRT-PCR gene expression assays for PD end points;and 5) PK data analysis. Large instrumentation in the Resource consists of two LC/MS/MS instruments, two HPLCs, one UPLC, an Atomic Absorption Spectrophotometer and a real-time qRT-PCR instrument. Small-molecular quantification includes several antimetabolites, taxanes, topoisomerase targeted agents, anthracyclines, Vitamin-D/metabolites, targeted agents (sunitinib) and other molecules such as tryptophan, kyurenine and novobiocin. Elemental analysis includes selenium, platinum and gold. The Resource is guided by a Steering Committee and operates on Institute support and chargebacks. Future plans for the Resource are to attract a larger peer-review-funded CCSG program user base, provide expanded support to Phase I/I I studies, expand the technical staff and add a fluorescence detector to the UPLC system. The Resource is used by all six Programs and 65% of users are CCSG members. $49,410 in CCSG support is requested, representing 9% of the total operating budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-36
Application #
8375986
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
36
Fiscal Year
2012
Total Cost
$104,240
Indirect Cost
$41,264
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Zonneville, Justin; Safina, Alfiya; Truskinovsky, Alexander M et al. (2018) TGF-? signaling promotes tumor vasculature by enhancing the pericyte-endothelium association. BMC Cancer 18:670
Mahoney, Martin C; Erwin, Deborah O; Twarozek, Annamaria Masucci et al. (2018) Leveraging technology to promote smoking cessation in urban and rural primary care medical offices. Prev Med 114:102-106
Cheng, Ting-Yuan David; Darke, Amy K; Redman, Mary W et al. (2018) Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). J Natl Cancer Inst 110:734-742
Elahi, Seerat; Egan, Shawn M; Holling, G Aaron et al. (2018) The RNA binding protein Ars2 supports hematopoiesis at multiple levels. Exp Hematol 64:45-58.e9
Rabi, Thangaiyan; Li, Fengzhi (2018) Multiple mechanisms involved in a low concentration of FL118 enhancement of AMR-MeOAc to induce pancreatic cancer cell apoptosis and growth inhibition. Am J Cancer Res 8:2267-2283
Haring, Rodney C; Henry, Whitney Ann; Hudson, Maui et al. (2018) Views on clinical trial recruitment, biospecimen collection, and cancer research: population science from landscapes of the Haudenosaunee (People of the Longhouse). J Cancer Educ 33:44-51
Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254
La Shu, Shin; Yang, Yunchen; Allen, Cheryl L et al. (2018) Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep 8:12905
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035
Gabriel, Emmanuel; Attwood, Kristopher; Al-Sukhni, Eisar et al. (2018) Age-related rates of colorectal cancer and the factors associated with overall survival. J Gastrointest Oncol 9:96-110

Showing the most recent 10 out of 1555 publications